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Abstract 
 
Although the technological change in medicine has been widely recognized as the 
major driver of rising healthcare costs, there is very little research that directly 
estimates this effect. This paper uses both a single-equation and a simultaneous 
equations approach to empirically investigate the interactive relationship between 
technological innovation and the growth of health expenditure in the context of the 
pharmaceutical market in Taiwan. Based on observing 182 therapeutic groups 
between 1997 and 2006, we find evidence to support the argument that technological 
innovation and health expenditure are simultaneously determined as technological 
innovation and the growth of health expenditure are endogenous rather than 
exogenous. Specifically, we find that therapeutic groups associated with higher 
pharmaceutical expenditure are likely to attract more new products to the market. 
Meanwhile, therapeutic groups with more new products are associated with higher 
pharmaceutical expenditures. An important implication of the paper is that the cost 
containment policy will not only affect the growth of health expenditure, but will also 
affect the progress of technological innovation in the health sector.  
 
 
Keywords: Technological innovation, new drugs, health expenditure, simultaneous 
equation model  
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Introduction 
Health expenditures measure a country‟s final consumption of health care goods 
and services plus capital investment in health care infrastructure. The international 
comparison of health expenditures reveals two stylized facts. First, at a point in time, 
there is substantial variation in health expenditures across countries, not only in terms 
of health expenditures, but also as a share of GDP. Second, over time, a large number 
of countries that have been studied, irrespective of whether their health expenditure 
levels were initially high or low, experience a similar trend in health expenditure 
growth. In particular, the growth rate of health expenditures has constantly exceeded 
the growth rate of GDP.  
These stylized facts have provided an impetus for research on the causes of these 
increases. The bulk of the empirical evidence provides consistent findings on the 
determinants of personal health expenditures. National income (that is, GDP per 
capita) is the most important determinant of the cross-sectional variation in health 
expenditures (see Gerdtham et al. [9]). While differences in income alone can explain 
most of the cross-sectional variation in health expenditures, growth in income cannot 
explain why health expenditures have risen so substantially over time. Other factors, 
such as population aging, increased coverage of health insurance, growth in the 
number of health professionals and hospital capacity, and lower productivity growth 
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in the service sector than in other sectors of the countries‟ economies, may explain 
part of the story. However, Newhouse [19] explained that the above-mentioned factors, 
taken together, can only account for less than half of the long-run growth in health 
expenditures. Instead, Newhouse [19] argued that the major part of the increase in 
health expenditures stems from technological change in health care. Included in 
technological change are newly-developed types of equipment and pharmaceuticals as 
well as new surgical technologies and the development and diffusion of such 
technological tools as renal dialysis.  
This view is supported by empirical evidence and is also widely accepted by 
health economists [8, 21]. However, researchers have traditionally treated 
technological change in medicine as an exogenous factor, but technological change in 
medicine – like technological change in the economy as a whole – is, in fact, 
endogenous, or generated by factors within the healthcare system.
1
  
The purpose of this paper is to investigate empirically the determinants of the 
technological change in medicine and its impact on healthcare costs. Specifically, we 
estimate a two-equation model that contains both technological innovation and health 
expenditure. We compare the empirical results from treating technological innovation 
as an endogenous variable as compares with treating it as an exogenous variable in the 
                                                 
1 An exception is Okunade and Murthy [21]. They used the Granger causality test to check the 
exogeneity of technological innovation, instead of treating technological innovation as exogenous. 
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simultaneous equation model. As a substantial amount of technological progress in 
medicine has taken the form of pharmaceutical innovation in recent years, we use the 
pharmaceutical market as an example to test our hypothesis regarding exogeneity 
versus endogeneity. Specifically, we test the following two hypotheses: (1) the 
therapeutic groups associated with higher pharmaceutical expenditure are likely to 
attract more entries of new products; and (2) the therapeutic groups associated with 
more pharmaceutical innovation tend to have higher levels of pharmaceutical 
expenditure. 
The remainder of the paper is organized as follows. Section 2 provides a review 
of the research that investigates the effects of technological change on the growth of 
health expenditure, and the determinants that affect the progress of technological 
change. Section 3 briefly describes the features of the pharmaceutical market in 
Taiwan. Section 4 provides an analytical framework to explain the interaction 
between the entry of new drugs and health care costs. Section 5 describes the data and 
methodology used in the empirical analysis. Section 6 presents and analyzes the 
empirical results, and Section 7 summarizes the findings and discusses some policy 
implications. 
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Previous Research 
Since the publication of the seminal paper in Kleiman [11] and Newhouse [20], 
the determinants of health expenditure have been the focus of research in the field of 
health economics. A considerable number of studies in this line highlight the role of 
income to explain cross-country variations and long-run growth in health expenditure 
[2-4]. However, little attention has been given to testing the role of technological 
innovation in accounting for health expenditure growth. A plausible explanation for 
the paucity of such research is that searching for an appropriate proxy for 
technological change in medicine can be difficult.  
Okunade and Murthy [21] overcame this difficulty by using total R&D 
spending and R&D spending specific to health care in the United States as proxies for 
health care technology. They found empirical evidence in support of Newhouse‟s [19] 
argument that technological change is a statistically significant long-run driver of the 
rising health care expenditure.  
Although the research that directly estimates the effects of technological 
innovation on rising healthcare costs has been scarce, a growing body of research has 
paid attention to the effect of technological change in medicine on improvements in 
population health which, in turn, provides additional information on alternative 
measures of technological innovation in practice. Along this line of research, some 
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studies have focused on technological change in medicine, in general, while others 
have focused on pharmaceutical innovation, in particular. For example, Papageorgious, 
Savvides and Zachariadis [22] argued that the rest of the world may benefit from 
medical technological change occurring in countries at the frontier of medical 
technology. They measured the diffusion of technological change in medicine by 
medical imports as well as the diffusion in the forms of ideas, e.g., the number of 
foreign-trained medical students.  
Other studies that have focused specifically on pharmaceutical innovation rely on 
three different types of proxies to measure technological change: (1) the cumulative 
number of drugs approved with new molecular entities; (2) newer drugs as a 
proportion of total prescriptions; and (3) the average vintage of drugs [13-15]. For 
example, Lichtenberg [15] used the first approach and emphasized that approval of 
new molecular entities represents the most important form of innovation. Using the 
cumulative number of new molecular entities available in the market by year, 
Lichtenberg [15] found a significantly positive relationship between his measure of 
pharmaceutical innovation and life expectancy in the USA and in a sample containing 
data from 52 countries. 
These studies treat technological change as an exogenous variable, and hence do 
not address the issue of how the technological change in medicine evolves over time. 
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As noted by Smith et al. [23], the rate of technological innovation does not expand 
independently of the historical context but is rather influenced by various factors, 
such as the size of the market, rising income and more generous insurance coverage. 
As a result, a growing body of research has attempted to explain the major drivers of 
technological innovation in health care.  
 In this line of research, we illustrate two studies that have documented the 
empirical relationship between the size of the market and the progress of 
pharmaceutical innovation. First, using data from the USA, Finkelstein [6] 
investigated whether an increase in market size resulting from changes in health 
policies affects R&D investment behavior in the vaccine industry.
2
 By comparing 
changes in the number of new vaccine clinical trials between treatment diseases 
(affected by the policies) and control diseases (not affected by the policies), she found 
evidence that the expansion of market size induced by changes in health policies has 
significantly positive effect on rates of innovation in vaccine markets. The estimates 
indicate that a $1 increase in annual expected market revenue from a vaccine leads to 
                                                 
2
 In 1991, the U.S. Centers for Disease Control recommended that all infants be 
vaccinated against hepatitis B. In 1993, Medicare provided insurance coverage for 
influenza vaccinations administered to its beneficiaries. These two policies increased 
the potential market size for vaccines which, in turn, in combination with the adoption 
of a no-fault compensation system for injuries attributable to use of certain childhood 
vaccines in 1986, substantially increased the expected return from developing new 
vaccines for infectious diseases. 
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a six cent increase in vaccine R&D investment. 
Second, Acemoglu and Linn [1] measured changes in market size from 
demographic trends in the USA. During a recent 30-year period, demographic trends 
led to a decline in the market for drugs mostly consumed by the young (age 0-30). In 
contrast, markets for drugs mostly consumed by the middle-aged have increased. 
Acemoglu and Linn [1] found that the change in potential market size, which is 
measured by a combination of the number of consumers and their incomes, has a 
significantly positive impact on pharmaceutical innovation: a one percent increase in 
potential market size leads to about a four percent increase in the entry of new drugs. 
In addition, the rate of technological innovation is influenced by rising incomes 
and more generous insurance coverage. Hall and Jones [10] developed a conceptual 
framework for explaining why health expenditures are commanding a rising share of 
national income in many high-income countries. In their framework, they argued that 
the marginal utility of non-health-care consumption is declining, but that the utility of 
spending on health is not. As a result, nations spend an increasing share of their 
income on health care as their national incomes rise. This argument is supported by 
empirical evidence that the value of life increases twice as fast as income which, in 
turn, implies that people are willing to pay more for technological innovation as their 
incomes rise.  
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As Finkelstein [7] noted, a major expansion in health insurance coverage, which 
occurred when Medicare was introduced, would lead to market-wide changes. The 
substantial increases in the demand for care which lead to corresponding increases in 
revenue are likely to be sufficient to more than offset the fixed cost of entry (e.g., 
building a new facility, or obtaining regulatory approval for entry). Thus, given the 
fact that a major demand stimulus occurred, one can expect many providers to enter 
the market. Furthermore, rates of return on medical research and development are 
likely to increase, leading to a substantial amount of technological change. This 
argument is supported by the empirical evidence. Finkelstein [7] found that the 
introduction of the U.S. Medicare program led to substantial new hospital entry and 
new technology adoption.  
In summary, the previous research has documented the empirical relationship 
that technological change in medicine is endogenous in the sense that the rate of 
technological innovation is influenced by various factors inherent in the health care 
system, such as the size of the market, income and health insurance. The 
technological innovation, in turn, becomes a major driver of rising healthcare costs. 
Based on these previous studies, we test empirically the determinants of the 
technological innovation and their impact on health expenditures in the context of the 
pharmaceutical market in Taiwan – a country with rapid economic growth and 
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universal health insurance.
3
 
Background 
Taiwan initiated the National Health Insurance (NHI) program on March 1, 1995, 
which covers all citizens. The insurance coverage includes outpatient services, 
inpatient services and prescription drugs. After implementing the NHI program, the 
adoption of NHI formula is an important avenue for new prescription drugs to enter 
into the Taiwanese pharmaceutical market, as most physicians generally prescribe 
only those drugs that are reimbursed by the NHI program. In the Bureau of NHI, a 
public agency in charge of administering the NHI program in Taiwan, there is a 
pharmaceutical committee comprised of physicians, government officials, and 
academics, to determine the NHI formula. After drugs have obtained the approval and 
licenses for marketing from the Department of Health, most of these prescription 
drugs will be included in the NHI formula if the single public payer and 
pharmaceutical manufacturers reach an agreement on the level of the regulated 
reimbursement prices. There have been around 25,700 drug items that have been 
approved in the NHI formula. In 2011, there are still around 16,700 drug items 
reimbursed by the NHI program.
4
 
With respect to the reimbursement scheme, the initial reimbursement prices of 
                                                 
3 The mean annual growth rate during the period 1997-2006 is around 4.4%. 
4 Source: http://www.nhi.gov.tw/ 
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on-patent branded drugs are based on the median prices of ten developed countries, 
and the upper limit price of off-patent branded drugs is around 85% of the 
international median price.
5
 Thereafter, the reimbursement prices will be updated 
based on a two-year price survey and adjustment. On the demand side, currently the 
maximum copayment of pharmaceuticals is only NT$ 200, resulting in the brands of 
drugs for patients mainly those determined by physicians.
6
  
Thus, the feature of the Taiwanese pharmaceutical market is that the retail prices 
of new drugs are regulated by a universal health insurance program [18]. As previous 
research has focused only on the elderly population by using Medicare data [7] or 
obtaining results from competitive pharmaceutical and health insurance markets [1], 
this paper provides empirical evidence in the context of the pharmaceutical market 
regulated by a universal health insurance program which covers the entire population. 
Empirical Framework 
To test our hypothesis, an empirical model is constructed using two equations: 
the entry of new drugs and pharmaceutical expenditure. Equations explaining the 
determinants of new drugs (NEW) and pharmaceutical expenditure (EXP) are given 
as follows:  
1 2 3it it it itNEW EXP X                                         (1) 
                                                 
5 The BNH includes Australia, Belgium, Canada, France, Germany, Japan, Sweden, Switzerland, UK 
and USA as a reference group for international comparison. 
6 The average exchange rate during the period 1997-2006 is US$1=NT$32.7. 
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1 2 3it it it itEXP NEW Z                                          (2) 
where i denotes the therapeutic category and t indexes the year, Xit and Zit are vectors 
of control variables pertaining to the determinants of the technological innovation and 
pharmaceutical expenditure, respectively, and ε and μ are random error terms. As 
NEW and EXP are determined simultaneously, NEW and EXP are hypothesized 
endogenous variables.  
In order to test the endogeneity of EXP and NEW, the one-period lagged values 
of EXP and NEW are used as suitable instruments to test the null hypothesis of 
exogeneity (whereby OLS and IV estimates of the parameters in equations (1) and (2) 
are asymptotically equivalent) against the alternative hypothesis of endogeneity 
(wherein the OLS and IV estimates converge to different constants). The Hausman 
[11] test enables a test of whether the OLS and IV estimates are significantly different 
from each other, in which case EXP and NEW are endogenous. 
In addition, we need to use exclusion restrictions to identify the parameters for 
the simultaneous equations model. The lagged value of EXP is solely in the NEW 
equation, and the lagged value of NEW is used only in the EXP equation. Thereafter, 
we use three-stage least squares (3SLS) to estimate the simultaneous relationship 
between NEW and EXP by using the covariance matrix from the second stage and 
suitable instruments for the endogenous explanatory variables.  
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The fixed-effects method and 181 therapeutic dummies are used to control for 
the unobservable characteristics of the therapeutic groups that may be correlated with 
the endogenous variables. In addition, the log transformation model is used to 
estimate equation (2) as the distribution of the pharmaceutical expenditures tends to 
be skewed to the right. 
The Data and Variables 
The data used in this paper are from two sources. First, we obtained data on new 
drugs included in the formula of the NHI program from the Bureau of National Health 
Insurance. This data set provides information regarding the drug identification 
number (ID), ingredient name, brand name, dosage, reimbursement price, and the 
anatomical therapeutic chemical (ATC) code classification system.  
Second, we obtained data on pharmaceutical expenditures and other variables 
from a longitudinal data set, which contains one million individuals (about 5% of the 
total population in Taiwan) randomly selected from the registry of NHI beneficiaries 
in 2005. The sampling file was then merged with insurance claim files that trace back 
all the medical utilization records of the same individuals in each year and follow 
their medical utilization data for subsequent years, hereafter referred to as the NHI 
sampling claims data.  
The NHI sampling claims data were made publicly available through the 
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National Health Research Institute. This data set contains detailed records on the 
utilization of personal health-care services, including outpatient visits, hospital 
admissions and prescription drugs. The data on prescription drugs provide the drug 
identification number, the quantity utilized and total drug expenditures. The advantage 
of this data set is that all the medical utilization data can be linked together for the 
same patient. In addition, this data set is based on national sampling data and serves 
as an adequate representation of the population data. Thus, the summation of drug 
expenditure across all patients represents the aggregate spending for the same drug in 
Taiwan.  
Between 1996 and 2006, 556 new drugs were added to the NHI formula.
7
 Table 
1 shows the distribution of these new drugs across therapeutic groups (defined by the 
first level of the ATC code). The therapeutic groups that have relatively more 
pharmaceutical innovation, as measured by the total accumulated numbers of new 
drugs included in the NHI formula during the sample period, include drugs for the 
central nervous system (N), antineoplastic and immunomodulating agents (L), 
anti-infectives (J), as well as drugs for the alimentary tract and metabolism (A), and 
for the cardiovascular system (C). The number of new drugs in these five groups 
accounts for about 62% of all new drugs. In contrast, the expenditure on drugs for 
                                                 
7 In the data set, the forms of new prescription drugs include new molecular entities, formulations, 
combinations, and indications. 
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these five groups accounted for nearly 75% of NHI pharmaceutical expenditure in 
2006. This suggests that therapeutic groups with relatively more pharmaceutical 
innovation are associated with higher shares of pharmaceutical expenditure. 
Alternatively, this also suggests that the therapeutic groups with higher expenditure 
shares are likely to attract more entries of new products.  
In this paper, the observation unit is the therapeutic category, as defined by a 
four-digit ATC code.
8
 As can be seen in the last column of Table 1, the total number 
of therapeutic categories in our data set is 182. The sample covers the period from 
1997 to 2006, which gives a balanced panel model with 1,820 observations. 
Table 2 illustrates the definitions and summary statistics of the variables. The 
first key variable in our empirical analysis is the technological innovation. Following 
the approach adopted in Lichtenberg [15], we measure the technological innovation in 
the pharmaceutical market by the accumulated number of new pharmaceutical 
products in each therapeutic category, as given by the variable NEW.
 9
 This variable 
ranges from 0 to 27 in the data set, with a mean of 1.63, indicating that there is 
substantial variation in pharmaceutical innovation across therapeutic groups.  
The second key variable in our empirical analysis is the size of the market which 
                                                 
8 In the ATC classification system, the one-digit, three-digit, four-digit, and five-digit codes represent 
the anatomical main group (1st level), therapeutic subgroup (2nd level), pharmacological subgroup (3rd 
level), and chemical subgroup (4th level), respectively. 
9 A new pharmaceutical product is defined here as one that was included in the NHI formula after 
1996.  
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is measured by the annual pharmaceutical expenditure in each therapeutic group. This 
variable is represented by the variable EXP and expressed in real terms (in 2006 New 
Taiwan dollars). There is also a substantial variation in annual pharmaceutical 
expenditure across therapeutic groups. 
Other control variables used in the empirical analysis include the characteristics 
of the demand side and supply side of the market within each therapeutic group, as 
well as the major reforms of the payment system in Taiwan. The demand-side 
variables include mean age of patients who utilize the drugs in each therapeutic 
categories and the number of patients (PT) that use drugs. The supply-side variables 
include: (1) the competition in the pharmaceutical market, as measured by the 
Herfindahl-Hirschman index (HHI) in each therapeutic group; and (2) the size of the 
buyer, which is measured by the market share (in terms of NHI drug expenditure) of 
products purchased by larger hospitals, including academic medical centers and 
metropolitan hospitals (HOSB).  
We also add a dummy variable to control the effect of the payment system 
reform. The variable representing the implementation of the hospital global budget 
(GB) is set to 0 before 2002, and to 1 thereafter, to measure the impact of the payment 
system reform for the hospital sector that came into effect in July 2002.  
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Empirical Results 
The empirical results are presented in Table 3. The second and third columns of 
Table 3 contain the results for the therapeutic fixed effects model, as estimated by 
OLS, while the fourth and fifth columns in Table 3 shows the results for the 
therapeutic fixed effects as estimated by IV, that is, by treating EXP and NEW as 
endogenous variables. The last two columns of Table 3 illustrate the results for the 
fixed effect model estimated by 3SLS, using 181 dummy variables for the therapeutic 
categories. 
The Hausman test statistics shown at the bottom of Table 3 lead to rejection of 
the null hypothesis that EXP and NEW are exogenous, in which case they are 
endogenous. Therefore, the OLS estimates will be biased and inconsistent, and hence 
lead to biased inferences regarding the simultaneous determination of technological 
innovation and health expenditure. Based on the fixed effect model estimated by 
3SLS, the elasticity of technological innovation with respect to pharmaceutical 
expenditure is 1.1481, which is about 46.5% ((1.1481-0.7836)/0.7836) larger than that 
estimated by single-equation IV method. Similarly, we find the elasticity of 
pharmaceutical expenditure with respect to technological innovation is 0.2139, as 
estimated by the fixed effect model estimated by 3SLS. This value is about 43.8 % 
((0.2139-0.1487)/0.1487) larger than that estimated by the single-equation IV method.  
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These results suggest that technological innovation and the growth of health 
expenditure create an interactive and reinforcing cycle. Thus, the effect of 
technological innovation on the growth of health expenditure will be biased if 
estimation fails to take into account the interactive nature of technological change in 
medicine. Thus, we base the following discussion on the simultaneous equations 
model that accounts for the endogeneity of EXP and NEW using the 3SLS method. 
As expected, the coefficients of EXP are positive and statistically significant, 
indicating that an increase in the size of the market, as measured by the NHI 
pharmaceutical expenditure, leads to more rapid progress in technological change in 
medicine, as measured by the accumulated number of new pharmaceutical products. 
The estimates indicate that a 10% increase in pharmaceutical expenditures leads to an 
increase of 11.5% in the entry of new drugs (elasticity = 1.8714/1.63). Moreover, the 
entry of new pharmaceutical products significantly increases pharmaceutical 
expenditures. The estimated elasticity reported in the fifth column of Table 3 is about 
0.21 (= 0.1312*1.63), indicating that a 10% increase in the entry of new drugs leads 
to an increase of 2.1% in the pharmaceutical expenditure.  
Combining these two effects, the results suggest that technological change in 
medicine and the growth of health expenditure are simultaneously determined as they 
are both endogenous variables. On the one hand, an increase in health expenditure 
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implies an expansion in the size of the market which, in turn, provides strong 
incentives for technological innovation. In other words, as long as new technology is 
a normal good, the increase in incomes in conjunction with more resources allocated 
to the health care sector over time will lead to greater utilization of new-technology 
treatments. Moreover, the health insurance coverage of prescription drugs is quite 
generous in Taiwan, thereby creating an incentive for new drugs to be included in the 
NHI formula. 
On the other hand, an increase in the rate of technological innovation introduces 
more new pharmaceutical products into the health care system which in turn fuel the 
rise in health expenditure. Previous research indicates that because of the higher 
prices and progress of new technology, the adoption of new drugs might increase 
health expenditures through two channels: treatment substitution and treatment 
expansion [5]. Liu and Hsieh [17] show that the adoption of new oral hypoglycemic 
agents, like thiazolidinediones, increases the treatment cost of diabetes patients and 
the effect of treatment substitution is greater than that of treatment expansion. 
With regard to the estimated coefficients of other control variables, the results 
are in general consistent with prior expectations. On the demand side, we find that the 
estimated coefficients for the number and average age of patients (PT and AGE) and 
are positive and statistically significant in the EXP equation, indicating that 
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therapeutic groups, in which the products are used by more elderly patients, are more 
likely to have higher costs.  
On the supply side, we find that the degree of market concentration is negatively 
associated with the entry of new products. This result suggests that a highly 
competitive market is likely to attract the entry of more new products.  
We also find that the buyer size within the therapeutic group have a significantly 
positive impact on both the entry of new products and pharmaceutical expenditures. 
This result indicates that therapeutic markets with more big buyers, as measured by 
the higher market share of larger hospitals, are more likely to attract new products to 
enter the market which, in turn, also have a more significant impact on the growth of 
pharmaceutical expenditures. This finding, in combination with the previous results, 
suggests that not only market size, but also the distribution of the market size toward 
larger buyers, have significant impacts on the entry of new products. A plausible 
explanation for this result is that larger buyers may help the supplier to save on 
marketing costs, and hence increase their expected returns. Thus, pharmaceutical 
firms are more likely to develop new products where their markets are concentrated 
toward larger hospitals.  
The coefficients of GB are significantly positive in the equation of 
pharmaceutical expenditure, indicating that the implementation of global budgets 
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might increase the market size of pharmaceutical markets. This might stem from the 
nature of policy design that the pharmaceutical expenditure is removed from the 
overall budget before the reimbursement rate of non-drug treatments is determined, 
and the reimbursement rate of drugs is based on the public regulated price that is 
known prior to the delivery of the health care service. That is, under the current rule 
of global budgeting in Taiwan, the reimbursement price for non-drug treatment is 
variable, but the reimbursement price for drug treatment is fixed. Thus, in order to 
avoid the uncertainty in hospital revenues generated from non-drug treatments, 
hospitals have incentives to spend more on drugs.  
Finally, we find that the estimated coefficient of the variable measuring the time 
trend is positive and significant in the NEW equation, indicating that the entry of new 
drugs increase over time. 
Conclusion 
This paper uses a simultaneous equations approach to investigate empirically the 
dynamic interactions between technological innovation and the growth of health 
expenditures. Using the pharmaceutical market in Taiwan for the 1997-2006 period, 
this paper has led to several important findings. First, we find that therapeutic groups 
associated with higher pharmaceutical expenditures are more likely to attract the entry 
of more new products. The estimated elasticity, which measures the responsiveness of 
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technological innovation with respect to health expenditure, is greater than 1, 
suggesting that the technological innovation is strongly influenced by market size. 
Second, the results also confirm the previous finding of Okunade and Murthy [21] 
in that technological innovation is an important driver of rising health care costs. The 
results show that the estimated elasticity, which measures the responsiveness of health 
expenditure with respect to technological innovation, is 0.21. 
Third, the Hausman test statistics indicate that technological innovation in 
medicine is endogenous in the simultaneous relationship with health expenditures. In 
addition, the estimated elasticity derived from the fixed effect model estimated by 
3SLS is significantly different from that derived from the same model estimated by 
single-equation IV. This finding suggests that the effect of technological innovation on 
the growth of health expenditure will be statistically biased if we fail to take into 
account the simultaneity problem between technological innovation and health 
expenditure. 
The empirical results of the paper have three important policy implications. First, 
technological changes in medicine and health expenditure are simultaneously 
determined in the sense that they work together and reinforce each other. Thus, the 
cost containment policy adopted in the health sector becomes a double-edged sword: 
it not only reduces the growth rate of health expenditure, but also reduces the rate of 
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technological innovation. Given that the technological change in medicine is an 
important contributor to improvements in the population‟s health, the simultaneous 
determination of technological innovation and health expenditure should lead the 
government to face a more severe policy dilemma in trying to control health care 
costs while also improving the population‟s health. 
Second, given that the public sector funds the major portion of the health care 
expenditure in many countries, the public sector often chooses “new technology” as 
the target of a cost containment policy. As technological innovation is endogenous in 
the sense that many factors beyond the control of the public sector provide fuel to 
induce the progress of new technology (e.g., market size and income), the cost 
containment effort may not effectively control the growth of health expenditures. 
Rather, such a policy just shifts the financing of new technology from the public to 
the private sector. An increase in the private financing of new technology may become 
an access barrier to new technology among low-income populations. For the supply 
side, the cost containment policy may also decrease the rate of return for new-drug 
investment, thereby reducing the incentives for pharmaceutical innovation. 
Third, improving health status is the main goal of health care policy, rather than 
containing health care costs. If the utilization of high-technology treatment improves 
health outcomes of the overall population, eventually the value of adopting 
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high-technology treatment might outweigh the increase in healthcare costs. 
Lichtenberg [16] shows that a higher quality of health care increases life expectancy, 
though it does increase health expenditures per capita. Therefore, creating a virtuous 
cycle between technological innovation and health expenditure by adopting new 
technology based on the cost-effective evidence would be an avenue for policy 
makers to shape their health care policy. 
One limitation of the paper is that we only focus on pharmaceutical innovations. 
Other forms of technological change in medicine, such as diagnostic technological 
progress, also account for a large part of growth in health care expenditure. Future 
research may use diagnostic technologies to investigate the interactive relationship 
between technological innovation and the growth of health expenditure. 
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Table 1 
Accumulated numbers of new drugs between 1996 and 2006 and NHI spending on 
prescription drugs in 2006, by ATC categories 
1st Level 
ATC Code 
 
Description 
 
Number of 
new drugs 
 
Share of all 
new drugs 
(%) 
 NHI drug 
expenditure 
(in billion 
NT$) 
 Share of 
total drug 
expenditure 
(%) 
 Number of 
therapeutic 
categories 
in our data 
   
  
 
N  Central nervous system  110  19.78 13.12 13.37  15 
L 
 
Antineoplastic and 
immunomodulating 
agents 
 
70  12.59  9.76  9.95  8 
J 
 
Antiinfectives for 
systemic use 
 
62 
 
 
11.15 
 
 
13.22 
 
 
13.47 
 
 14 
 
A 
 
Alimentary tract and 
metabolism 
 
55 
 
 
9.89 
 
 
12.70 
 
 
12.94 
 
 36 
 
C  Cardiovascular system  47  8.45  24.12  24.58  24 
B  Blood and blood 
forming organs 
 42  7.55  8.15  8.31  12 
       
R  Respiratory system  38  6.83  5.08  5.18  12 
D  Dermatologicals  35  6.29  1.31  1.34  16 
M  Musculoskeletal system  32  5.76  4.91  5.00  5 
S  Sensory organs  28  5.04  1.17  1.19  11 
G  Genitourinary system 
and sex hormones 
 24  4.32  2.36  2.41  13 
       
H 
 
Systemic hormonal 
preparations, excl. sex 
hormonal and insulin 
 
8 
 
 
 
1.44 
 
 
 
1.67 
 
 
 
1.7 
 
 
 9 
 
 
V  Various  5  0.90  0.38  0.39  3 
P 
 
Antiparasitic products, 
insecticides and 
repellents 
 
0  0.00  0.17  0.17  4 
Total    556  100.00  98.12  100.00  182 
Source: Bureau of National Health Insurance, Taipei, Taiwan. 
Notes: 1. ATC is the abbreviation of the Anatomical Therapeutic Chemical classification system. 
2. The amount of spending reported in this table excludes the NHI drug spending reimbursed by 
the flat payment system in clinics.  
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Table 2 Variable Definitions and Summary Statistics 
Name Definition Mean 
(Std. Deviation) 
Dependent 
variables 
  
NEW Number of accumulated new pharmaceutical 
products in each therapeutic category 
1.63 
(3.27) 
EXP
*
 Real annual pharmaceutical expenditure of 
each therapeutic category (in million NT$) 
11.90 
(24.36) 
Independent 
variables 
  
AGE Average age of patients who utilize the drugs 
in each therapeutic category 
44.47 
(12.87) 
PT Number of patients in each therapeutic 
category 
55649 
(109899) 
HHI Herfindahl-Hirschman Index in each 
therapeutic category 
0.2761 
(0.2261) 
HOSB The market share (in terms of NHI drug 
expenditure) of products purchased by 
academic medical centers and metropolitan 
hospitals  
0.6288 
(0.2155) 
GB Dummy = 1 after 2002 to represent the 
implementation of hospital global budget 
0.5 
(0.5) 
TREND Time trend 5.5 
(2.87) 
Number of 
observations 
  
1,820 
Note: The exchange rate was around 32.53 New Taiwan Dollars (TWD) per 1 US 
Dollar (USD) in 2006.  
Source: 2005 NHI sampling claims data, calculated by authors. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Regression Estimates 
Variables Fixed effects model 
estimated by OLS 
 Fixed effects estimated by IV  
(with lagged values as IV) 
 Simultaneous equation model (3SLS) 
with 181 therapeutic dummy variables++ 
(with lagged values as IV) 
NEW Log (EXP)  NEW Log (EXP) NEW Log (EXP) 
Log (EXP )
 + 1.3564*** 
(0.0912) 
[0.8321] 
  1.2772*** 
(0.0977) 
[0.7836] 
  1.8714*** 
(0.0898) 
[1.1481] 
 
NEW +  0.0881*** 
(0.0059) 
[0.1436] 
  0.0912*** 
(0.0062) 
[0.1487] 
  0.1312*** 
(0.0057) 
[0.2139] 
AGE 0.0306* 
(0.0173) 
0.0402*** 
(0.0043) 
 0.0446** 
(0.0176) 
0.0374*** 
(0.0043) 
 0.0210 
(0.0165) 
0.0339*** 
(0.0041) 
PT 6.44e-06*** 
(2.17e-06) 
3.17e-06*** 
(5.49e-07) 
 3.55e-06 
(2.70e-06) 
4.82e-06*** 
(6.63e-07) 
 6.31e-06 
(2.54e-06) 
4.29e-06*** 
(6.23e-07) 
HHI -1.7248*** 
(0.4148) 
-0.0124 
(0.1063) 
 -1.0957** 
(0.4329) 
0.0658 
(0.1077) 
 -0.8519** 
(0.4071) 
0.1300 
(0.1013) 
HOSB 0.8651* 
(0.4572) 
0.7953*** 
(0.1149) 
 1.4995*** 
(0.4761) 
0.7487*** 
(0.1178) 
 1.0584** 
(0.4475) 
0.6648*** 
(0.1108) 
GB -0.0278 
(0.1495) 
0.0558** 
(0.0381) 
 0.0355 
(0.1460) 
0.0972*** 
(0.0363) 
 0.0493 
(0.1373) 
0.0992*** 
(0.0341) 
TREND 0.1781*** 
(0.0284) 
-0.0114 
(0.0073) 
 0.1541*** 
(0.0306) 
-0.0235*** 
(0.0077) 
 0.1327*** 
(0.0288) 
-0.0325*** 
(0.0072) 
Const. -21.2232*** 
(1.3356) 
12.2515*** 
(0.2042) 
 -20.9196*** 
(1.4475) 
12.3644*** 
(0.2095) 
 -27.0991*** 
(1.3571) 
12.4144*** 
(0.2056) 
         
R2 0.3304 0.3168  0.2241 0.3929  0.8333 0.9713 
Hausman(p-value)    0.000 0.000    
Obs. 1820 1820  1638 1638  1638 1638 
Note: Fixed effects are for 182 therapeutic categories. *** 1% significance level; ** 5% significance level; *10% significance level 
Standard errors are in parentheses. + Elasticities are in brackets. ++ The therapeutic dummies are not shown here to save space. 
